300436.SZ
广生堂
SZSE · Healthcare · C 制造业 · CN
CNY 89.66
−3.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 417.2M | 416.4M | 441.5M | 422.7M | 385.8M |
| Cost of Revenue | 155.9M | 156.9M | 167.4M | 180.0M | 158.8M |
| Gross Profit | 261.3M | 259.5M | 274.1M | 242.7M | 227.0M |
| Operating Expenses | |||||
| R&D Expense | 39.2M | 31.8M | 44.1M | 133.0M | 185.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 110.1M | 111.5M | 112.5M | 114.9M | 85.4M |
| Selling & Marketing Expense | 199.7M | 203.1M | 199.2M | 189.8M | 177.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 391.6M | 388.5M | 399.4M | 477.2M | 462.0M |
| Cost and Expenses | 547.5M | 545.3M | 566.8M | 657.3M | 620.8M |
| Operating Income (EBIT) | (227.6M) | (227.7M) | (164.5M) | (295.5M) | (160.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (229.2M) | (229.3M) | (164.4M) | (298.0M) | (163.4M) |
| Income Tax Expense | 13.2M | 12.6M | 8.1M | 76.9M | (22.9M) |
| Bottom Line | |||||
| Net Income | (215.3M) | (217.8M) | (156.3M) | (348.6M) | (127.4M) |
| Earnings from Cont. Ops | (242.4M) | (241.8M) | (172.5M) | (374.9M) | (140.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (215.3M) | (217.8M) | (156.3M) | (348.6M) | (127.4M) |
| Per Share | |||||
| Basic EPS | (CN¥1.35) | (CN¥1.37) | (CN¥0.98) | (CN¥2.19) | (CN¥0.80) |
| Diluted EPS | (CN¥1.35) | (CN¥1.37) | (CN¥0.98) | (CN¥2.19) | (CN¥0.80) |
| Revenue Per Share | CN¥2.62 | CN¥2.61 | CN¥2.77 | CN¥2.65 | CN¥2.42 |
| Shares | |||||
| Basic Shares Outstanding | 159.2M | 159.3M | 159.3M | 159.3M | 159.2M |
| Diluted Shares Outstanding | 159.2M | 159.3M | 159.3M | 159.3M | 159.2M |
| Profitability Metrics | |||||
| EBITDA | — | (129.3M) | (63.8M) | (218.3M) | (98.8M) |
| D&A | — | 98.4M | 100.7M | 77.2M | 61.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026